In the realm of immunity, inhibiting glycolysis in breast cancer patients via the CEBPB pathway impedes G‐CSF and GM‐CSF production, reducing myeloid‐derived suppressor cells (MDSCs) and enhancing anti‐tumour immunity.39 Here, CSF3 is linked to neoplasm.